Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 91

Related Articles by Review for PubMed (Select 17319743)

1.

Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells.

Cheng C, Gall JG, Kong WP, Sheets RL, Gomez PL, King CR, Nabel GJ.

PLoS Pathog. 2007 Feb;3(2):e25.

2.

Immune response to helper dependent adenoviral mediated liver gene therapy: challenges and prospects.

Seiler MP, Cerullo V, Lee B.

Curr Gene Ther. 2007 Oct;7(5):297-305. Review.

PMID:
17979676
3.

Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy.

Jooss K, Chirmule N.

Gene Ther. 2003 Jun;10(11):955-63. Review.

PMID:
12756416
4.

Targeted adenoviral vectors.

Barnett BG, Crews CJ, Douglas JT.

Biochim Biophys Acta. 2002 May 3;1575(1-3):1-14. Review.

PMID:
12020813
5.
6.

Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors.

Seregin SS, Amalfitano A.

Expert Opin Biol Ther. 2009 Dec;9(12):1521-31. doi: 10.1517/14712590903307388. Review.

PMID:
19780714
7.

Adenovirus vectors composed of subgroup B adenoviruses.

Sakurai F, Kawabata K, Mizuguchi H.

Curr Gene Ther. 2007 Aug;7(4):229-38. Review.

PMID:
17969556
8.

Biophysical targeting of adenovirus vectors for gene therapy.

Silman NJ, Fooks AR.

Curr Opin Mol Ther. 2000 Oct;2(5):524-31. Review.

PMID:
11249755
9.

Improvements in gene therapy: averting the immune response to adenoviral vectors.

Ritter T, Lehmann M, Volk HD.

BioDrugs. 2002;16(1):3-10. Review.

PMID:
11908997
10.

INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.

[No authors listed]

Drugs R D. 2007;8(3):176-87. Review.

PMID:
17472413
11.

Adenovirus vector-based vaccines for human immunodeficiency virus type 1.

Barouch DH, Nabel GJ.

Hum Gene Ther. 2005 Feb;16(2):149-56. Review.

PMID:
15761255
12.

Adenoviral vectors for gene therapy.

Douglas JT.

Mol Biotechnol. 2007 May;36(1):71-80. Review.

PMID:
17827541
13.

[Characterization of adenovirus serotype 35 vectors using genetically modified animals and non-human primates].

Sakurai F, Kawabata K, Mizuguchi H.

Yakugaku Zasshi. 2006 Nov;126(11):1013-9. Review. Japanese.

14.
15.

Adenoviruses as vaccine vectors.

Tatsis N, Ertl HC.

Mol Ther. 2004 Oct;10(4):616-29. Review.

PMID:
15451446
16.

Immune responses to gene therapy vectors: influence on vector function and effector mechanisms.

Bessis N, GarciaCozar FJ, Boissier MC.

Gene Ther. 2004 Oct;11 Suppl 1:S10-7. Review.

PMID:
15454952
17.

Recombinant viruses as vaccines against viral diseases.

Souza AP, Haut L, Reyes-Sandoval A, Pinto AR.

Braz J Med Biol Res. 2005 Apr;38(4):509-22. Epub 2005 Apr 13. Review.

18.
19.

Molecular basis of the inflammatory response to adenovirus vectors.

Liu Q, Muruve DA.

Gene Ther. 2003 Jun;10(11):935-40. Review.

PMID:
12756413
20.

[Cell receptors for human adenoviruses].

Boulanger P.

J Soc Biol. 1999;193(1):77-84. Review. French.

PMID:
10851559
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk